Q3 2024 Collplant Biotechnologies Ltd Earnings Call Transcript
Key Points
- CollPlant Biotechnologies Ltd (CLGN) has advanced its preclinical study for regenerative breast implants, showing promising results in implant vascularization and tissue ingrowth.
- The company's proprietary rhCollagen technology is highly characterized and does not elicit an immune response, making it ideal for tissue regeneration.
- CollPlant's collaboration with AbbVie on a dermal and soft tissue filler product has the potential to create a paradigm shift in the aesthetics market.
- The company is actively pursuing additional collaboration partnerships to secure non-dilutive cash and expand the use of its rhCollagen technology.
- CollPlant showcased its technology at the International Society for Biofabrication, gaining interest and opening new collaboration opportunities with academic institutes.
- CollPlant Biotechnologies Ltd (CLGN) reported a significant decrease in GAAP revenues for Q3 2024, from $43,000 in Q3 2023 to $4,000, primarily due to planned delivery schedules with its largest customer.
- The company experienced a GAAP gross loss of $268,000 for Q3 2024, compared to a loss of $235,000 in Q3 2023.
- Operating expenses remain high, with GAAP operating expenses for Q3 2024 at $4.3 million, only slightly reduced from $4.4 million in Q3 2023.
- CollPlant's net loss for the nine months ended September 30, 2024, was $12.7 million, a significant increase from a net loss of $2.3 million for the same period in 2023.
- The company faces challenges in securing new agreements for its collagen technology, with no specific timeline for when new agreements might be finalized.
Greetings, and welcome to the CollPlant Biotechnologies third quarter 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce Dory Kurowski with LifeSci Advisors. Thank you. You may begin.
I would like to welcome everyone to CollPlant Biotechnologies financial results conference call to discuss the results for the third quarter ended September 30, 2024, where management will also provide a corporate business update.
With us on the call today from CollPlant are Yehiel Tal, Chief Executive Officer, who will provide an overview of the company's programs and associated updates; and Eran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CollPlant financial results for the second quarter ending September 30, 2024. Both will be able to answer questions at the end of the call.
Before we get started, I would like to remind everyone that statements made on this conference call may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
